Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEstrogens, esterified
Identification
- Name
- Estrogens, esterified
- Accession Number
- DB09381
- Type
- Small Molecule
- Groups
- Approved
- Description
Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis.
- Synonyms
- Esterified Estrogens
- Estrogens, Esterified Component of Menrium
- Estrogens,esterified
- Menrium Component Estrogens, Esterified
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Estragyn Tablet 0.3 mg Oral Searchlight Pharma Inc 1980-12-31 Not applicable Canada 
Estragyn Tablet 0.625 mg Oral Searchlight Pharma Inc 1974-12-31 Not applicable Canada Neo Estrone Tab 1.25mg Tablet 1.25 mg Oral Neolab Inc 1974-12-31 2008-04-02 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Menest Tablet 1.25 mg/1 Oral Physicians Total Care, Inc. 2010-12-16 Not applicable US 
Menest Tablet, film coated .3 mg/1 Oral Pfizer Laboratories Div Pfizer Inc. 1977-09-28 Not applicable US Menest Tablet, film coated 1.25 mg/1 Oral Pfizer Laboratories Div Pfizer Inc. 1977-09-28 Not applicable US Menest Tablet, film coated .625 mg/1 Oral Avera Mc Kennan Hospital 2015-11-23 Not applicable US Menest Tablet .3 mg/1 Oral Physicians Total Care, Inc. 2010-12-09 Not applicable US Menest Tablet, film coated 2.5 mg/1 Oral Pfizer Laboratories Div Pfizer Inc. 1977-09-28 2017-10-18 US Menest Tablet, film coated .625 mg/1 Oral Pfizer Laboratories Div Pfizer Inc. 1977-09-28 Not applicable US Menest Tablet .625 mg/1 Oral Physicians Total Care, Inc. 2008-09-05 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Covaryx Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet, coated Oral Centrix Pharmaceutical 2007-04-01 Not applicable US 
Covaryx Hs Estrogens, esterified (.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet, coated Oral Centrix Pharmaceutical 2007-04-01 Not applicable US Eemt Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet, coated Oral Creekwood Pharmaceuticals, Inc. 2011-09-01 Not applicable US Eemt Hs Estrogens, esterified (.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet, coated Oral Creekwood Pharmaceuticals, Inc. 2011-09-01 Not applicable US Esterified Estrogens and Methyltestosterone Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet Oral Method Pharmaceuticals 2017-08-15 Not applicable US Esterified Estrogens and Methyltestosterone Estrogens, esterified (.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet Oral ANI Pharmaceuticals, Inc. 2010-12-22 Not applicable US Esterified Estrogens and Methyltestosterone Estrogens, esterified (.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet Oral Method Pharmaceuticals 2017-08-15 Not applicable US Esterified Estrogens and Methyltestosterone Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet Oral ANI Pharmaceuticals, Inc. 2010-12-22 Not applicable US - International/Other Brands
- Amnestrogen / Estratab / Evex / Femogen
- Categories
- UNII
- 3ASP8Q3768
- CAS number
- Not Available
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Esterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the body. It is also indicated for the treatment of symptoms of breast cancer in both men and women. In men it can be used for the treatment of advanced prostate cancer. It is also indicated for the treatment of menopausal symptoms.
- Associated Conditions
- Pharmacodynamics
Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause.
- Mechanism of action
Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones.
- Absorption
Readily absorbed after oral administration. High concentrations of estrone are achieved with oral administration, whereas higher concentrations of estradiol are generally achieved after percutaneous absorption. Although vaginal products (such as gel, rings, etc.) are administered locally, they achieve high serum concentrations.
- Volume of distribution
The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentration in the sex hormone target organs.
- Protein binding
Approximately 95-98% of estradiol is bound loosely to albumin or tightly to sex hormone binding globulin.
- Metabolism
Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in postmenopausal women.
- Route of elimination
Mainly urinary as estradiol, estrone, estriol, and their glucuronide and sulfate conjugates.
- Half life
Half-life varies, it is in the range 1-2 hr.
- Clearance
There is variation in the clearance rate depends on each estrogen individual: estradiol-17β: 580 L/day/m2 estrone: 4050 L/day/m2 estriol: 1110 L/day/m2
- Toxicity
LD50 IP 325 mg/Kg (rat). LD50 IV 1740 mg/Kg (mouse). LD50 oral >5000 mg/Kg (rat).
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Estrogens, esterified. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be increased when it is combined with Estrogens, esterified. Experimental, Illicit 5-androstenedione The serum concentration of 5-androstenedione can be increased when it is combined with Estrogens, esterified. Experimental, Illicit Abciximab Estrogens, esterified may decrease the anticoagulant activities of Abciximab. Approved Aceclofenac Aceclofenac may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Acenocoumarol Estrogens, esterified may decrease the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetaminophen Acetaminophen may increase the thrombogenic activities of Estrogens, esterified. Approved Acetyl sulfisoxazole The metabolism of Estrogens, esterified can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetylsalicylic acid Acetylsalicylic acid may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved Alclometasone The serum concentration of Alclometasone can be increased when it is combined with Estrogens, esterified. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Estrogens, esterified. Experimental, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Estrogens, esterified. Experimental, Investigational Amcinonide The serum concentration of Amcinonide can be increased when it is combined with Estrogens, esterified. Approved Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Estrogens, esterified. Approved Aminosalicylic Acid Aminosalicylic Acid may increase the thrombogenic activities of Estrogens, esterified. Approved Amiodarone The metabolism of Estrogens, esterified can be decreased when combined with Amiodarone. Approved, Investigational Anastrozole The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrogens, esterified. Approved, Investigational Ancrod Estrogens, esterified may decrease the anticoagulant activities of Ancrod. Approved, Investigational Androstenedione The serum concentration of Androstenedione can be increased when it is combined with Estrogens, esterified. Experimental, Illicit Anecortave The serum concentration of Anecortave can be increased when it is combined with Estrogens, esterified. Investigational anecortave acetate The serum concentration of anecortave acetate can be increased when it is combined with Estrogens, esterified. Investigational Anthrax immune globulin human Estrogens, esterified may increase the thrombogenic activities of Anthrax immune globulin human. Approved Antipyrine Antipyrine may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Antithrombin III human Estrogens, esterified may decrease the anticoagulant activities of Antithrombin III human. Approved Antrafenine Antrafenine may increase the thrombogenic activities of Estrogens, esterified. Approved Apalutamide The serum concentration of Estrogens, esterified can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban Estrogens, esterified may decrease the anticoagulant activities of Apixaban. Approved Aprepitant The serum concentration of Estrogens, esterified can be increased when it is combined with Aprepitant. Approved, Investigational Ardeparin Estrogens, esterified may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Estrogens, esterified may decrease the anticoagulant activities of Argatroban. Approved, Investigational Atamestane The serum concentration of Atamestane can be increased when it is combined with Estrogens, esterified. Investigational Atazanavir The metabolism of Estrogens, esterified can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Estrogens, esterified can be decreased when combined with Atomoxetine. Approved Balsalazide Balsalazide may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Becaplermin Estrogens, esterified may decrease the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estrogens, esterified. Approved, Investigational Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Bivalirudin Estrogens, esterified may decrease the anticoagulant activities of Bivalirudin. Approved, Investigational Bortezomib The metabolism of Estrogens, esterified can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Estrogens, esterified can be decreased when it is combined with Bosentan. Approved, Investigational Bromfenac Bromfenac may increase the thrombogenic activities of Estrogens, esterified. Approved Budesonide The serum concentration of Budesonide can be increased when it is combined with Estrogens, esterified. Approved Bufexamac Bufexamac may increase the thrombogenic activities of Estrogens, esterified. Approved, Experimental Capromab pendetide Estrogens, esterified may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Capsaicin Capsaicin may increase the thrombogenic activities of Estrogens, esterified. Approved Carbamazepine The metabolism of Estrogens, esterified can be increased when combined with Carbamazepine. Approved, Investigational Carprofen Carprofen may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved, Withdrawn Celecoxib Celecoxib may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Ceritinib The serum concentration of Estrogens, esterified can be increased when it is combined with Ceritinib. Approved Certoparin Estrogens, esterified may decrease the anticoagulant activities of Certoparin. Approved, Investigational Chenodeoxycholic acid The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Estrogens, esterified. Approved Chlorphenesin Chlorphenesin may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved, Withdrawn Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the thrombogenic activities of Estrogens, esterified. Approved Ciclesonide The serum concentration of Ciclesonide can be increased when it is combined with Estrogens, esterified. Approved, Investigational Cimicoxib Cimicoxib may increase the thrombogenic activities of Estrogens, esterified. Investigational Cisplatin Cisplatin may increase the thrombogenic activities of Estrogens, esterified. Approved Citric Acid Estrogens, esterified may decrease the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clarithromycin The metabolism of Estrogens, esterified can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Estrogens, esterified can be decreased when combined with Clemastine. Approved, Investigational Clobetasol The serum concentration of Clobetasol can be increased when it is combined with Estrogens, esterified. Approved, Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be increased when it is combined with Estrogens, esterified. Approved Clobetasone The serum concentration of Clobetasone can be increased when it is combined with Estrogens, esterified. Approved Clocortolone The serum concentration of Clocortolone can be increased when it is combined with Estrogens, esterified. Approved Clodronic Acid Clodronic Acid may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational, Vet Approved Clotrimazole The metabolism of Estrogens, esterified can be decreased when combined with Clotrimazole. Approved, Vet Approved Conestat alfa Estrogens, esterified may increase the thrombogenic activities of Conestat alfa. Approved, Investigational Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Estrogens, esterified. Approved, Investigational Cortexolone 17α-propionate The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Estrogens, esterified. Investigational Corticosterone The serum concentration of Corticosterone can be increased when it is combined with Estrogens, esterified. Experimental Cortisone acetate The serum concentration of Cortisone acetate can be increased when it is combined with Estrogens, esterified. Approved, Investigational Crizotinib The metabolism of Estrogens, esterified can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Estrogens, esterified can be decreased when combined with Curcumin. Approved, Investigational Cyclosporine The metabolism of Estrogens, esterified can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Estrogens, esterified may decrease the anticoagulant activities of Dabigatran etexilate. Approved Dabrafenib The serum concentration of Estrogens, esterified can be decreased when it is combined with Dabrafenib. Approved, Investigational Dalteparin Estrogens, esterified may decrease the anticoagulant activities of Dalteparin. Approved Danaparoid Estrogens, esterified may decrease the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Estrogens, esterified may decrease the anticoagulant activities of Darexaban. Investigational Darunavir The metabolism of Estrogens, esterified can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Estrogens, esterified can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Estrogens, esterified can be decreased when it is combined with Deferasirox. Approved, Investigational Deflazacort The serum concentration of Deflazacort can be increased when it is combined with Estrogens, esterified. Approved, Investigational Delavirdine The metabolism of Estrogens, esterified can be decreased when combined with Delavirdine. Approved Desirudin Estrogens, esterified may decrease the anticoagulant activities of Desirudin. Approved Desonide The serum concentration of Desonide can be increased when it is combined with Estrogens, esterified. Approved, Investigational Desoximetasone The serum concentration of Desoximetasone can be increased when it is combined with Estrogens, esterified. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Estrogens, esterified. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Estrogens, esterified. Experimental, Vet Approved Dexamethasone The serum concentration of Dexamethasone can be increased when it is combined with Estrogens, esterified. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Estrogens, esterified. Vet Approved Dexibuprofen Dexibuprofen may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Dexketoprofen Dexketoprofen may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Dextran Estrogens, esterified may decrease the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Diclofenac Diclofenac may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved Dicoumarol Estrogens, esterified may decrease the anticoagulant activities of Dicoumarol. Approved Diflorasone The serum concentration of Diflorasone can be increased when it is combined with Estrogens, esterified. Approved Diflunisal Diflunisal may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Difluocortolone The serum concentration of Difluocortolone can be increased when it is combined with Estrogens, esterified. Approved, Investigational, Withdrawn Difluprednate The serum concentration of Difluprednate can be increased when it is combined with Estrogens, esterified. Approved Dihydroergotamine The metabolism of Estrogens, esterified can be decreased when combined with Dihydroergotamine. Approved, Investigational Diltiazem The metabolism of Estrogens, esterified can be decreased when combined with Diltiazem. Approved, Investigational Doxycycline The metabolism of Estrogens, esterified can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Estrogens, esterified can be decreased when combined with Dronedarone. Approved Drospirenone Drospirenone may increase the thrombogenic activities of Estrogens, esterified. Approved Droxicam Droxicam may increase the thrombogenic activities of Estrogens, esterified. Withdrawn Dyphylline The serum concentration of Dyphylline can be increased when it is combined with Estrogens, esterified. Approved Edetic Acid Estrogens, esterified may decrease the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Estrogens, esterified may decrease the anticoagulant activities of Edoxaban. Approved Enoxaparin Estrogens, esterified may decrease the anticoagulant activities of Enoxaparin. Approved Enzalutamide The serum concentration of Estrogens, esterified can be decreased when it is combined with Enzalutamide. Approved Equilenin The serum concentration of Equilenin can be increased when it is combined with Estrogens, esterified. Experimental Equilin The serum concentration of Equilin can be increased when it is combined with Estrogens, esterified. Approved Erythromycin The metabolism of Estrogens, esterified can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Estrone The serum concentration of Estrone can be increased when it is combined with Estrogens, esterified. Approved Estrone sulfate The serum concentration of Estrone sulfate can be increased when it is combined with Estrogens, esterified. Approved Etanercept Etanercept may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Ethyl biscoumacetate Estrogens, esterified may decrease the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac Etodolac may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational, Vet Approved Etoricoxib Etoricoxib may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Exemestane The therapeutic efficacy of Exemestane can be decreased when used in combination with Estrogens, esterified. Approved, Investigational Fenoprofen Fenoprofen may increase the thrombogenic activities of Estrogens, esterified. Approved Ferulic acid Estrogens, esterified may decrease the anticoagulant activities of Ferulic acid. Experimental Fish oil Fish oil may increase the thrombogenic activities of Estrogens, esterified. Approved, Nutraceutical Fluasterone The serum concentration of Fluasterone can be increased when it is combined with Estrogens, esterified. Investigational Fluconazole The metabolism of Estrogens, esterified can be decreased when combined with Fluconazole. Approved, Investigational Fludrocortisone The serum concentration of Fludrocortisone can be increased when it is combined with Estrogens, esterified. Approved, Investigational Fluindione Estrogens, esterified may decrease the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone The serum concentration of Flumethasone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Flunisolide The serum concentration of Flunisolide can be increased when it is combined with Estrogens, esterified. Approved, Investigational Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrogens, esterified. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be increased when it is combined with Estrogens, esterified. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be increased when it is combined with Estrogens, esterified. Approved, Withdrawn Fluorometholone The serum concentration of Fluorometholone can be increased when it is combined with Estrogens, esterified. Approved, Investigational Fluprednidene The serum concentration of Fluprednidene can be increased when it is combined with Estrogens, esterified. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be increased when it is combined with Estrogens, esterified. Approved Flurandrenolide The serum concentration of Flurandrenolide can be increased when it is combined with Estrogens, esterified. Approved Flurbiprofen Flurbiprofen may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Fluticasone The serum concentration of Fluticasone can be increased when it is combined with Estrogens, esterified. Approved, Experimental, Investigational Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Estrogens, esterified. Approved Fluticasone propionate The serum concentration of Fluticasone propionate can be increased when it is combined with Estrogens, esterified. Approved Fluvoxamine The metabolism of Estrogens, esterified can be decreased when combined with Fluvoxamine. Approved, Investigational Fondaparinux Estrogens, esterified may decrease the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Estrogens, esterified may decrease the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Formestane The serum concentration of Formestane can be increased when it is combined with Estrogens, esterified. Approved, Investigational, Withdrawn Fosamprenavir The metabolism of Estrogens, esterified can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Estrogens, esterified can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Estrogens, esterified can be increased when combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Estrogens, esterified can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabexate Estrogens, esterified may decrease the anticoagulant activities of Gabexate. Investigational Ginseng Ginseng may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational, Nutraceutical Halcinonide The serum concentration of Halcinonide can be increased when it is combined with Estrogens, esterified. Approved, Investigational, Withdrawn HE3286 The serum concentration of HE3286 can be increased when it is combined with Estrogens, esterified. Investigational Heparin Estrogens, esterified may decrease the anticoagulant activities of Heparin. Approved, Investigational Human C1-esterase inhibitor Estrogens, esterified may increase the thrombogenic activities of Human C1-esterase inhibitor. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrogens, esterified. Approved, Investigational Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Ibuprofen Ibuprofen may increase the thrombogenic activities of Estrogens, esterified. Approved Icosapent Icosapent may increase the thrombogenic activities of Estrogens, esterified. Approved, Nutraceutical Idelalisib The metabolism of Estrogens, esterified can be decreased when combined with Idelalisib. Approved Idraparinux Estrogens, esterified may decrease the anticoagulant activities of Idraparinux. Investigational Imatinib The metabolism of Estrogens, esterified can be decreased when combined with Imatinib. Approved Indinavir The metabolism of Estrogens, esterified can be decreased when combined with Indinavir. Approved Indomethacin Indomethacin may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Isavuconazole The serum concentration of Estrogens, esterified can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Estrogens, esterified can be decreased when combined with Isavuconazonium. Approved, Investigational Isradipine The metabolism of Estrogens, esterified can be decreased when combined with Isradipine. Approved, Investigational Istaroxime The serum concentration of Istaroxime can be increased when it is combined with Estrogens, esterified. Investigational Itraconazole The metabolism of Estrogens, esterified can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Estrogens, esterified can be increased when it is combined with Ivacaftor. Approved Ketoconazole The metabolism of Estrogens, esterified can be decreased when combined with Ketoconazole. Approved, Investigational Ketoprofen Ketoprofen may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved Ketorolac Ketorolac may increase the thrombogenic activities of Estrogens, esterified. Approved Lenalidomide Estrogens, esterified may increase the thrombogenic activities of Lenalidomide. Approved Lepirudin Estrogens, esterified may decrease the anticoagulant activities of Lepirudin. Approved Letaxaban Estrogens, esterified may decrease the anticoagulant activities of Letaxaban. Investigational Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Estrogens, esterified. Approved Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Estrogens, esterified. Approved, Vet Approved Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Estrogens, esterified. Approved Lopinavir The metabolism of Estrogens, esterified can be decreased when combined with Lopinavir. Approved Lornoxicam Lornoxicam may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Lorpiprazole The serum concentration of Estrogens, esterified can be increased when it is combined with Lorpiprazole. Approved Loteprednol The serum concentration of Loteprednol can be increased when it is combined with Estrogens, esterified. Approved Lovastatin The metabolism of Estrogens, esterified can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Estrogens, esterified can be increased when it is combined with Luliconazole. Approved Lumiracoxib Lumiracoxib may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Magnesium salicylate Magnesium salicylate may increase the thrombogenic activities of Estrogens, esterified. Approved ME-609 The serum concentration of ME-609 can be increased when it is combined with Estrogens, esterified. Investigational Meclofenamic acid Meclofenamic acid may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved Medrysone The serum concentration of Medrysone can be increased when it is combined with Estrogens, esterified. Approved Mefenamic acid Mefenamic acid may increase the thrombogenic activities of Estrogens, esterified. Approved Melagatran Estrogens, esterified may decrease the anticoagulant activities of Melagatran. Experimental Melengestrol The serum concentration of Melengestrol can be increased when it is combined with Estrogens, esterified. Vet Approved Meloxicam Meloxicam may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved Mesalazine Mesalazine may increase the thrombogenic activities of Estrogens, esterified. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Mifepristone The metabolism of Estrogens, esterified can be decreased when combined with Mifepristone. Approved, Investigational Mitotane The serum concentration of Estrogens, esterified can be decreased when it is combined with Mitotane. Approved Mometasone The serum concentration of Mometasone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Morniflumate Morniflumate may increase the thrombogenic activities of Estrogens, esterified. Approved Nabumetone Nabumetone may increase the thrombogenic activities of Estrogens, esterified. Approved Nadroparin Estrogens, esterified may decrease the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Estrogens, esterified may decrease the anticoagulant activities of Nafamostat. Approved, Investigational Naproxen Naproxen may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved NCX 1022 The serum concentration of NCX 1022 can be increased when it is combined with Estrogens, esterified. Investigational Nefazodone The metabolism of Estrogens, esterified can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Estrogens, esterified can be decreased when combined with Nelfinavir. Approved Nepafenac Nepafenac may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Netupitant The serum concentration of Estrogens, esterified can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Estrogens, esterified can be increased when combined with Nevirapine. Approved Niflumic Acid Niflumic Acid may increase the thrombogenic activities of Estrogens, esterified. Approved Nilotinib The metabolism of Estrogens, esterified can be decreased when combined with Nilotinib. Approved, Investigational Nimesulide Nimesulide may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational, Withdrawn Olaparib The metabolism of Estrogens, esterified can be decreased when combined with Olaparib. Approved Oleoyl-estrone The serum concentration of Oleoyl-estrone can be increased when it is combined with Estrogens, esterified. Investigational Osimertinib The serum concentration of Estrogens, esterified can be increased when it is combined with Osimertinib. Approved Ospemifene The risk or severity of adverse effects can be increased when Estrogens, esterified is combined with Ospemifene. Approved, Investigational Otamixaban Estrogens, esterified may decrease the anticoagulant activities of Otamixaban. Investigational Oxaprozin Oxaprozin may increase the thrombogenic activities of Estrogens, esterified. Approved Palbociclib The serum concentration of Estrogens, esterified can be increased when it is combined with Palbociclib. Approved, Investigational Paramethasone The serum concentration of Paramethasone can be increased when it is combined with Estrogens, esterified. Approved Parecoxib Parecoxib may increase the thrombogenic activities of Estrogens, esterified. Approved Pentaerythritol Tetranitrate Estrogens, esterified may decrease the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentobarbital The metabolism of Estrogens, esterified can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pentosan Polysulfate Estrogens, esterified may decrease the anticoagulant activities of Pentosan Polysulfate. Approved Phenindione Estrogens, esterified may decrease the anticoagulant activities of Phenindione. Approved, Investigational Phenobarbital The metabolism of Estrogens, esterified can be increased when combined with Phenobarbital. Approved, Investigational Phenprocoumon Estrogens, esterified may decrease the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone Phenylbutazone may increase the thrombogenic activities of Estrogens, esterified. Approved, Vet Approved Phenytoin The metabolism of Estrogens, esterified can be increased when combined with Phenytoin. Approved, Vet Approved Piroxicam Piroxicam may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Pitolisant The serum concentration of Estrogens, esterified can be decreased when it is combined with Pitolisant. Approved, Investigational Pomalidomide Pomalidomide may increase the thrombogenic activities of Estrogens, esterified. Approved Posaconazole The metabolism of Estrogens, esterified can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Potassium Citrate Estrogens, esterified may decrease the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Estrogens, esterified. Approved, Investigational, Nutraceutical Prasterone sulfate The serum concentration of Prasterone sulfate can be increased when it is combined with Estrogens, esterified. Investigational Prednicarbate The serum concentration of Prednicarbate can be increased when it is combined with Estrogens, esterified. Approved, Investigational Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be increased when it is combined with Estrogens, esterified. Approved, Experimental, Investigational Primidone The metabolism of Estrogens, esterified can be increased when combined with Primidone. Approved, Vet Approved Protein C Estrogens, esterified may decrease the anticoagulant activities of Protein C. Approved Protein S human Estrogens, esterified may decrease the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Estrogens, esterified may decrease the anticoagulant activities of Protocatechualdehyde. Approved Ranolazine The metabolism of Estrogens, esterified can be decreased when combined with Ranolazine. Approved, Investigational Resveratrol Resveratrol may increase the thrombogenic activities of Estrogens, esterified. Approved, Experimental, Investigational Reviparin Estrogens, esterified may decrease the anticoagulant activities of Reviparin. Approved, Investigational Rimexolone The serum concentration of Rimexolone can be increased when it is combined with Estrogens, esterified. Approved Rivaroxaban Estrogens, esterified may decrease the anticoagulant activities of Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational, Withdrawn Ropinirole The serum concentration of Ropinirole can be increased when it is combined with Estrogens, esterified. Approved, Investigational Rucaparib The metabolism of Estrogens, esterified can be decreased when combined with Rucaparib. Approved, Investigational Salicylic acid Salicylic acid may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational, Vet Approved Salsalate Salsalate may increase the thrombogenic activities of Estrogens, esterified. Approved Saquinavir The metabolism of Estrogens, esterified can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Sarilumab. Approved, Investigational Seliciclib Seliciclib may increase the thrombogenic activities of Estrogens, esterified. Investigational Sildenafil The metabolism of Estrogens, esterified can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Estrogens, esterified can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Estrogens, esterified can be increased when it is combined with Simeprevir. Approved Sodium Citrate Estrogens, esterified may decrease the anticoagulant activities of Sodium Citrate. Approved, Investigational Somatotropin The therapeutic efficacy of Somatotropin can be decreased when used in combination with Estrogens, esterified. Approved, Investigational St. John's Wort The serum concentration of Estrogens, esterified can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Estrogens, esterified can be increased when it is combined with Stiripentol. Approved Sulfasalazine Sulfasalazine may increase the thrombogenic activities of Estrogens, esterified. Approved Sulfisoxazole The metabolism of Estrogens, esterified can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac Sulindac may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational Sulodexide Estrogens, esterified may decrease the anticoagulant activities of Sulodexide. Approved, Investigational Suprofen Suprofen may increase the thrombogenic activities of Estrogens, esterified. Approved, Withdrawn Talniflumate Talniflumate may increase the thrombogenic activities of Estrogens, esterified. Approved Telaprevir The metabolism of Estrogens, esterified can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Estrogens, esterified can be decreased when combined with Telithromycin. Approved Tenoxicam Tenoxicam may increase the thrombogenic activities of Estrogens, esterified. Approved Thalidomide Estrogens, esterified may increase the thrombogenic activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The serum concentration of Theophylline can be increased when it is combined with Estrogens, esterified. Approved Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Estrogens, esterified. Approved Tiaprofenic acid Tiaprofenic acid may increase the thrombogenic activities of Estrogens, esterified. Approved Ticlopidine The metabolism of Estrogens, esterified can be decreased when combined with Ticlopidine. Approved Tipranavir Estrogens, esterified may increase the dermatologic adverse activities of Tipranavir. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be increased when it is combined with Estrogens, esterified. Approved, Withdrawn Tocilizumab The serum concentration of Estrogens, esterified can be decreased when it is combined with Tocilizumab. Approved Tolmetin Tolmetin may increase the thrombogenic activities of Estrogens, esterified. Approved Triamcinolone The serum concentration of Triamcinolone can be increased when it is combined with Estrogens, esterified. Approved, Vet Approved Trolamine salicylate Trolamine salicylate may increase the thrombogenic activities of Estrogens, esterified. Approved Troxerutin Estrogens, esterified may decrease the anticoagulant activities of Troxerutin. Investigational Ulobetasol The serum concentration of Ulobetasol can be increased when it is combined with Estrogens, esterified. Approved Ursodeoxycholic acid The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Estrogens, esterified. Approved, Investigational Valdecoxib Valdecoxib may increase the thrombogenic activities of Estrogens, esterified. Approved, Investigational, Withdrawn Vemurafenib The serum concentration of Estrogens, esterified can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Estrogens, esterified can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Estrogens, esterified can be decreased when combined with Verapamil. Approved Vitamin C The serum concentration of Estrogens, esterified can be increased when it is combined with Vitamin C. Approved, Nutraceutical Warfarin Estrogens, esterified may decrease the anticoagulant activities of Warfarin. Approved Ximelagatran Estrogens, esterified may decrease the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Ziprasidone The metabolism of Estrogens, esterified can be decreased when combined with Ziprasidone. Approved - Food Interactions
- Not Available
References
- General References
- External Links
- PubChem Substance
- 347910451
- Wikipedia
- Esterified_estrogens
- AHFS Codes
- 68:16.04 — Estrogens
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Hot Flushes, Menopause, Postmenopause 1 2 Completed Treatment Menopause 1 2 Terminated Treatment Cancer, Breast 1 2 Terminated Treatment Menopause 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Tablet, coated Oral Tablet Oral Tablet Oral 0.3 mg Tablet Oral 0.625 mg Tablet Oral .3 mg/1 Tablet Oral .625 mg/1 Tablet Oral 1.25 mg/1 Tablet, film coated Oral .3 mg/1 Tablet, film coated Oral .625 mg/1 Tablet, film coated Oral 1.25 mg/1 Tablet, film coated Oral 2.5 mg/1 Tablet Oral 1.25 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
Drug created on November 30, 2015 12:10 / Updated on June 21, 2018 00:05